ACADIA PHARMACEUTICALS INC (ACAD) 16.89 +0.61 (+3.75%)
16.89 +0.61 (+3.75%)
US0042251084 - Common Stock
Fundamental Rating
Overall ACAD gets a fundamental rating of 5 out of 10. We evaluated ACAD against 638 industry peers in the Biotechnology industry. Both the profitability and the financial health of ACAD get a neutral evaluation. Nothing too spectacular is happening here. ACAD is valued quite expensive, but it does show an excellent growth.
Profitability
Profitability Rating
ACAD has a Return On Assets of -33.39%. This is better than the industry average of -41.19%.
ACAD has a Profit Margin of -39.93%. This is amongst the best returns in the industry. The industry average is -408.39%. ACAD outperforms 81% of its industry peers.
ACAD has a Piotroski-F score of 5.00. This indicates an average health and profitability for ACAD.
The profitability ratios for ACAD are negative, so there is not much use analyzing them.
VS Industry
ROA (-33.39%) VS Industry: 64% outperformed.
-1,441.42
115.38
Profit Margin (-39.93%) VS Industry: 81% outperformed.
-1,173,705.71
8,610.80
Valuation
Valuation Rating
With a price book ratio of 6.29, ACAD is valued correctly.
The Price/Earnings Ratio is negative for ACAD. In the last year negative earnings were reported.
Also next year ACAD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
When comparing the price book ratio of ACAD to the average industry price book ratio of 1.62, ACAD is valued more expensive than its industry peers. 89% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Book (6.29) VS Industry: 11% outperformed.
171.17
0.09
Growth
Growth Rating
The Earnings Per Share has grown by an impressive 45.45% over the past year.
ACAD is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 15.15% yearly.
Looking at the last year, ACAD shows a quite strong growth in Revenue. The Revenue has grown by 10.57% in the last year.
Measured over the past 5 years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 94.71% on average per year.
The Revenue is expected to grow by 18.06% on average over the next 5 years. This is quite good.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 45.45% | -25.52% | 19.79% | 29.54% | 15.15% |
| Revenue | 94.71% | 29.33% | 10.57% | 8.58% | 13.19% | 16.8% | 18.06% |
Health
Health Rating
ACAD has a Current Ratio of 4.53. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.47 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has an Altman-Z score of 4.43. This indicates that ACAD is financially healthy and little risk of bankruptcy at the moment.
ACAD is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of -0.10.
The Debt to Equity ratio of ACAD is in line with the industry averages.
ACAD has a Piotroski-F score of 5.00. This indicates an average health and profitability for ACAD.
When comparing the Current Ratio of ACAD to the average industry Current Ratio of 6.52, ACAD is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.48, ACAD is worse placed to pay its short term obligations than its industry peers.
VS Industry
Debt/Equity (0) VS Industry: 43% outperformed.
18.24
0.00
Quick Ratio (4.47) VS Industry: 36% outperformed.
0.03
399.16
Current Ratio (4.53) VS Industry: 35% outperformed.
0.08
401.12
Altman-Z (4.43) VS Industry: 74% outperformed.
-1,821.48
293.92
Dividend
Dividend Rating
ACAD does not give a dividend.
ACADIA PHARMACEUTICALS INC16.89
NASDAQ:ACAD (9/27/2022, 8:48:49 AM)+0.61 (+3.75%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 08-08 2022-08-08/amc | Earnings (Next) | 11-07 2022-11-07 |
| Ins Owners | 0.16% | Inst Owners | 94.53% |
| Market Cap | 2.73B | Analysts | 70.77 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 5.33 | P/B | 6.29 |
| EV/EBITDA | -11.15 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | 45.45% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 22.22% |
| EPS Next Y | -25.52% | EPS Next 2Y | 19.79% |
| EPS Next 3Y | 29.54% | EPS Next 5Y | 15.15% |
| Revenue growth 1Y | 10.57% | Revenue growth 3Y | 29.33% |
| Revenue growth 5Y | 94.71% | Revenue growth Q2Q | 16.79% |
| Revenue Next Year | 8.58% | Revenue Next 2Y | 13.19% |
| Revenue Next 3Y | 16.8% | Revenue Next 5Y | 18.06% |
| Current Ratio | 4.53 | Quick Ratio | 4.47 |
| Altman-Z | 4.43 | F-Score | 5 |
| Debt/Equity | 0 | ||
| ROA | -33.39% | ROE | N/A |
| ROIC | N/A | ROICg | N/A |
| PM | -39.93 | OM | -40.32 |
| Asset Turnover | 0.84 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA